Drug intelligence / Profile preview

Rituximab + Vincristine + Fludarabine + Prednisone + Anakinra

Development stage: Unknown
Lead developer: IDEC
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral Or Intravenous, Oral, Subcutaneous

Overview

Rituximab + Vincristine + Fludarabine + Prednisone + Anakinra is a combination therapy involving several drugs with distinct mechanisms of action. - **Rituximab** is a monoclonal antibody targeting CD20, used in treating B-cell non-Hodgkin's lymphoma and rheumatoid arthritis[1][7]. - **Vincristine** is a vinca alkaloid that inhibits microtubule assembly, used in various cancer treatments[7]. - **Fludarabine** is a nucleoside analog that interferes with DNA synthesis, commonly used in treating leukemia[6][7]. - **Prednisone** is a corticosteroid with anti-inflammatory and immunosuppressive effects[7]. - **Anakinra** is an interleukin-1 receptor antagonist used primarily for treating rheumatoid arthritis[7].

Targets

CD20 (B-lymphocyte antigen CD20)RNR (Ribonucleotide reductase)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))POLA1 (DNA polymerase alpha)IL1R1 (Interleukin-1 Receptor Type 1)

Beyond the preview

Go deeper on Rituximab + Vincristine + Fludarabine + Prednisone + Anakinra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rituximab + Vincristine + Fludarabine + Prednisone + Anakinra.

Explore the full profile